macromolecular constituents, mucins, are a large reservoir of both carbon and nitrogen, and have 1 been measured at concentrations of up to 10 g/L in sputum 4 . These high molecular weight 2 glycoproteins are highly recalcitrant to bacterial degradation 5 , yet, they can serve as a major 3 nutrient source for niche-specific microbiota of the gut and oral cavity. For example, oral 4 streptococci produce a variety of glycolytic and proteolytic enzymes that liberate bioavailable 5 carbohydrates from salivary mucins 6 . In turn, these primary degraders modify the metabolic 6 landscape of the oral cavity and stimulate the growth of secondary colonizers 7 . Similar 7 interactions between commensal gut microbiota are also known 8 . By comparison, the role of 8 airway mucins as a nutrient source for opportunistic pathogens is poorly understood. Here, we 9 investigated mucins as a primary airway carbon source and characterized their potential to 10 sustain pathogen growth. Our results demonstrate that the primary pathogen of CF, Pseudomonas 11 aeruginosa, is unable to use mucins directly. This lack of growth raised the question: can other 12 members of the CF microbiota degrade mucins and alter the nutritional reservoir available for 13 pathogen growth? We subsequently found that co-culture of pathogens with oral-derived 14 anaerobes can stimulate pathogen growth using mucins as a sole carbon source. Finally, we 15 revealed that P. aeruginosa expresses pathways for the catabolism of mucin-derived 16 fermentation byproducts in vivo, strongly supporting a pathogenic role for commensal anaerobes 17 in the progression of CF lung disease. 18
Pseudomonas aeruginosa utilizes mucin inefficiently as a sole carbon source. 19 We first tested whether mucins alone could sustain the growth of P. aeruginosa. To do 20 so, we assayed strain PA14 for growth in a defined medium containing intact mucins from 21 porcine gastric mucin (PGM) as the sole carbon source (Figure 1a ). Interestingly, 10g/L mucin 22 (sugar equivalent of ~45mM glucose assuming 80% sugar by weight) only resulted in a moderate 23 OD 600 gain of 0.2 after 20 h. By contrast, PA14 grew to 0.8 OD on glucose (15mM), which 1 underscores the inability of PA14 to efficiently break down and utilize mucin glycoproteins. 2 Given that the PA14 laboratory strain was isolated from a burn wound 9 , we reasoned that 3 lung-derived clinical isolates would show enhanced growth on mucins. Growth yield of clinical 4 isolates was assayed long past the onset of stationary phase (60 h) to ensure there was no long 5 lag-phase or slow growth phenotypes. Under these conditions, CF-derived P. aeruginosa strains 6 CI46 and CI47 grew to an even lower density on mucin relative to PA14 (Figure 1b ). Growth on 7 mucin was also compared to growth with glucose alone, with and without the addition of an 8 amino acid supplement to account for auxotrophy, a common trait among CF isolates 10 . CI47 9 grew well with and without amino acids while CI46 grew poorly on glucose alone, suggesting an 10 auxotrophy that was corrected by the supplement. The ability of the clinical isolates to grow on 11 glucose supplemented with amino acids to a greater extent than the more nutrient-dense mucin 12 medium suggested that the lack of robust growth on mucin was not due to a slow-growth 13 phenotype. Rather, these data suggest that P. aeruginosa, including isolates derived from the 14 mucin-rich CF lung environment, are unable to efficiently utilize these complex glycoproteins in 15
monoculture. 16
Saliva-derived mucin fermenting bacteria support the growth of opportunistic pathogens in 17
vitro. 18
The inefficient use of mucins by P. aeruginosa motivated us to consider recent culture-19 independent studies of the lung microbiota for insights into the carbon flux of the airways. 20
Notably, obligately anaerobic taxa associated with the oral cavity (e.g. Prevotella, Veillonella) 21 have gained attention for their abundance in both healthy and diseased lungs [11] [12] [13] . A role for these 22 organisms in CF disease is controversial 14, 15 ; however, they have been characterized for their 23 ability to degrade and ferment both salivary and intestinal mucins 16, 17 , in turn supporting the 1 growth of secondary colonizers. Based on these observations, we hypothesized that oral-2 associated taxa alter the metabolic landscape of the airways by degrading respiratory mucins. 3
More specifically, we predicted that the fermentative degradation of mucin glycoproteins 4 liberates sugars, amino acids and short chain fatty acids (SCFAs) that are readily utilizable by P. 5 aeruginosa and other lung pathogens 18 . 6
To test whether fermenting taxa could stimulate CF pathogen growth, a saliva-derived 7 bacterial community was first enriched on mucin ( Supplementary Figure 1 ). The enrichment 8 culture was then used to inoculate an anaerobic minimal mucin medium supplemented with 1.0% 9 agar to mimic a high viscosity sputum gel 19 (Figure 2a ). Once solidified, PA14 was resuspended 10 in phosphate-buffered saline agar without mucin, and was overlaid on top of the mucin-enriched 11 bacterial community. Under these conditions, PA14 should only grow if provided with diffusible 12 metabolites from the lower phase. After 60 h growth, turbidity was noticeable in the lower phase 13 and a yellow-green pigment characteristic of P. aeruginosa was observed throughout the co-14 culture tube ( Figure 2A ). By contrast, in the absence of oral anaerobes, little pigment was 15 produced. Colony counts were also determined for P. aeruginosa, Achromobacter xylosoxidans, 16
and Staphylococcus aureus grown in the presence and absence of mucin-enriched bacteria 17 ( Figure 2b ). For each pathogen, significant differences (>10-fold; p<0.01) in growth were 18 observed in the presence of mucin fermenters relative to tubes in which oral anaerobes were 19 omitted. These data support the hypothesis that oral-derived microbiota can serve as primary 20 mucin degrading organisms in the CF airways, in turn liberating metabolites that can support the 21 growth of opportunistic pathogens. 22
Oral-associated bacteria are present in sputum and are enriched in anaerobic mucin 1 fermentation cultures. 2
To determine if there exists a fraction of the CF lung microbiota that has the ability to 3 degrade and ferment mucins, we performed enrichment experiments on sputum from 14 stable, 4 non-exacerbating CF patients. To do so, a small fraction of sputum was used to inoculate an 5 anaerobic culture with mucins supplied as the sole carbon source. Following growth, genomic 6 DNA was isolated from the initial sputum samples and corresponding enrichment cultures 7 followed by 16S rRNA gene sequencing to identify mucin-fermenting taxa. Consistent with 8 previous studies, sputum (prior to enrichment) harbored a diverse microbiota ( Figure 3a ) that 9 was highly variable between patients. As expected, Pseudomonas sp. made up the highest 10 percentage of sequence reads with a per-patient average of 31.3% across the cohort. Notably, 11 taxa previously characterized for their mucin-degrading activity (Prevotella, Veillonella, 12
Streptococcus, and Fusobacterium) also made up 35.1% of the population (11.4%, 9.7%, 9.9%, 13 and 4.1%, respectively). 14 Post-enrichment, communities were predominated by oral-associated fermenting 15 organisms ( Figure 3b Staphylococcus, and Pseudomonas were selected against (p<0.05). The high composition of 20 mucin-fermenting taxa in the initial sputum samples indicates a suitable niche space exists in the 21 CF lung for oral-associated mucin fermenting anaerobes. The enrichment results demonstrate 22 that these taxa found within sputum retain their mucin fermentation capacity during growth in 1 the lower airways, and could potentially cross-feed lung pathogens in vivo. 2
Mucin fermenting taxa are present within explanted CF lungs. 3
The presence of oral flora in the lower airways and their contribution to CF lung disease 4 progression is controversial due to the possibility of contamination from the route of 5 sampling 14, 15 . To address this concern, we sampled mucus directly from multiple lobes of three 6 explanted pairs of lungs derived from late-stage CF patients (Supplementary Table 1 ). Not 7 surprisingly, each lobe from all three patients harbored an abundance of Pseudomonas sp., which 8 is characteristic of late-stage lung disease 14, 20, 21 . Yet, two patients also contained a notable 9 proportion of mucin-fermenting taxa identified in our enrichment experiments. For example, the 10 left lingula (left middle lung) from patient A contained relatively diverse microbiota, of which 11 approximately 4.7% were Prevotella, Streptococcus, and Veillonella. Patient B harbored known 12 mucin-fermenting taxa (~7.9% of sequence reads) in the lower left lung. Patient C was 13 dominated (>99%) by Pseudomonas, but even in this patient, it is noteworthy that mucin-14 fermenting anaerobes were associated with several regions of the airways. Together, these data 15 support that a proportion of oral-associated anaerobes in our sputum samples were derived from 16 the lower airways. 17
Sputum-derived fermenting organisms produce short-chain fatty acids and amino acids 18 when grown on mucin. 19
To study the cross-feeding ability of mucin fermenters in further detail, we characterized 20 the metabolites that were generated during anaerobic mucin enrichment. To do so, we used 21 targeted high performance liquid chromatography (HPLC) for the quantification of organic acids 22 produced in mixed acid fermentation (acetate, butyrate, citrate, formate, isobutyrate, isovalerate, 23 ketobutyrate, ketoisovalerate, lactate, 2-methylbutyrate, propionate, succinate and valerate), and 1 gas chromatography for the quantification of amino acids. Mucin-enriched sputum cultures 2 generated high amounts of acetate (30.2 +/-9.7 mM) and propionate (15.4 +/-3.8 mM), while 3 only one enrichment sample containing an abundance of Streptococcus sp. (#7025, see Figure  4 3a) produced a detectable concentration of lactate (7.8 mM) ( Figure 4a ). No other SCFAs 5 assayed were found in the mucin-enrichment supernatants. Not surprisingly, free amino acids 6 were also present in each sample (1.37 +/-1.32 mM total) ( Figure 4b ), suggestive of their 7 liberation from the mucin polypeptide backbone. The abundance of amino acids correlates well 8 with previous studies of sputum composition where they were found to be present in appreciable 9 quantities 22 . These data demonstrate that acetate, propionate, and amino acids are byproducts of 10 mucin fermentation by sputum-derived anaerobes and suggest that they may be bioavailable 11 carbon sources that can cross-feed pathogens in vivo. 12
Cystic fibrosis sputum contains short-chain fatty acids and Pseudomonas aeruginosa 13
responds to propionate in vivo. 14 16S rRNA gene analyses demonstrated the presence of a fermentative bacterial 15 community in the CF airways. To provide further evidence of fermentative activity in vivo, we 16 used two complementary techniques: mass spectrometry and quantitative reverse transcription 17 PCR (qRTPCR). First, using gas chromatography mass spectrometry (GC-MS), acetate and 18 propionate were quantified in paired saliva/sputum samples collected from 9 stable CF patients. 19
These data revealed no significant differences for either SCFA between the oral cavity and lung 20 (Supplementary Figure 2) . Given the presence of fermenting taxa and SCFA previously 21 identified in saliva 23 , this result was not unexpected. To circumvent the effect of SCFA 22 contaminants from the mouth during sampling, an oral rinse was first performed, prior to saliva 23 and immediate sputum collection (see Methods). Using this sampling strategy on 7 additional 1 patients, acetate concentrations were significantly higher in sputum relative to saliva (5.9 +/-1.8 2 mM versus 2.4 +/-1.8, p<0.01) (Figure 5a ), consistent with metabolites generated during 3 enrichment culture (see Figure 4A ) and indicative of a fermentative bacterial community within 4 the CF lung. Propionate, on the other hand, showed no significant difference (p=0.89) between 5 paired samples ( Figure 5b ). This result was surprising given the high levels of propionate 6 generated during in vitro mucin enrichments. Because of this disparity, we hypothesized that 7 propionate, over acetate, is preferentially utilized by members of the CF lung community in a 8 cross-feeding relationship. 9
If SCFAs were simultaneously produced and consumed by the airway bacterial 10 community, we would expect the concentration of these metabolites to remain low, and genes 11 required for their catabolism to be highly expressed. To address this possibility, we used 12 qRTPCR to measure in vivo bacterial gene expression. Genomic content suggests that 13
Pseudomonas has committed pathways for both acetate and propionate catabolism (encoded by 14 acsA/B and prpBCD, respectively). Therefore, as a proxy of the use of mucin-derived 15 metabolites by P. aeruginosa, we targeted the in vivo expression of acsA (encoding acetyl-coA 16 synthetase) and prpD (methylcitrate lyase) relative to their expression levels under controlled 17 conditions. In vitro, acsA and prpD were differentially expressed by PA14 in the presence of 18 acetate (5.8-fold higher, p=0.02) and propionate (11.4-fold, p<0.01), respectively, relative to 19 growth on glucose alone ( Figure 6 ). When both SCFAs were present, prpD was expressed 20 significantly higher than acsA (p<0.01), which were both upregulated relative to the glucose 21 control (2.4 and 4.8-fold for acsA and prpD, respectively). When compared to in vitro cultures, 22
analysis of sputum revealed that prpD (5.4-fold, p=0.02) but not acsA (no change, p=0.98) was 23 upregulated. These data are indicative that propionate is generated in the airways of CF patients 1 and that P. aeruginosa both senses and catabolizes propionate in vivo, providing further evidence 2 that mucin-associated fermentative metabolisms contribute to the metabolic landscape of the CF 3 lung. 4
Metabolite constituents of expectorated sputum are known to support bacterial growth in 7 vitro 22,24,25 but the nutritional role of intact mucins has not been characterized. Previous studies 8 reported that mucins support the carbon demands of P. aeruginosa in vitro 26,27 ; however, these 9 studies included autoclaved preparations of commercial PGM that contain low molecular mass 10 impurities. In fact, when PGM was filtered and dialyzed in our study (leaving only intact, large 11 glycoproteins), P. aeruginosa inefficiently utilized mucins as a carbon source on their own. 12
Rather, in the presence of purified mucin, fermentative oral-associated bacteria were required to 13 stimulate pathogen growth. Moreover, we revealed that in vitro mucin fermentation generated 14 high concentrations of SCFAs and amino acids, which were both abundant (acetate) and utilized 15 by P. aeruginosa (propionate) in patient sputum. Together, these data provide strong evidence 16 for a central role of mucin fermentation in the carbon flux of lower airway disease and define a 17 pathogenic role for oral-associated anaerobes in the progression of CF-associated airway disease. 18
In vitro, degradation of O-linked glycans and the polypeptide backbone of mucin by 19 sputum-derived anaerobes generated an abundance of SCFAs and amino acids. Given the known 20 substrate utilization profile of P. aeruginosa 18 , these compounds also likely sustained pathogen 21 growth within the co-culture experiment. Consistent with recent studies 32,33 , SCFAs were also 22 found in sputum across our CF patient cohort. Because SCFAs serve as a reliable biomarker of 23 fermentative metabolism 34 , their universal presence suggests that bacterial fermentation is a ubiquitous metabolic activity in the CF airways. More specifically, our data suggest that the 1 fermentation of mucins is a likely origin for metabolites that have been shown to support growth 2 of Pseudomonas 22 in expectorated sputum. Moreover, the high levels of prpD expression 3 confirms that P. aeruginosa is both sensing and utilizing propionate in vivo, suggesting that the 4 lower-than-expected concentrations of this metabolite in sputum can be explained by its 5 consumption as opposed to a lack of production within the airway environment. 6
Our data create a compelling model for the role of oral anaerobes in the development of 7 CF lung disease, whereby pathogens cannot become established until mucin fermenters have 8 colonized the lower airways. In CF, impaired mucociliary clearance and defective 9 immunological responses increase the likelihood of oral anaerobe colonization and the 10 degradation of respiratory mucins. In turn, anaerobes left uninhibited can condition the lung 11 environment into a niche that is suitable for pathogens to thrive. Several lines of clinical 12 evidence support this model: (i) pediatric patients have asymptomatic primary colonization by 13 oral anaerobes 35, 36 prior to the establishment of chronic P. aeruginosa infections, (ii) routine 14 administration of broad-spectrum antibiotics is an effective therapy to delay the onset of chronic 15 colonization by P. aeruginosa and reduce the frequency of acute exacerbations 37,38 , and (iii) the 16 in vitro antibiotic susceptibility of lung pathogens does not correlate with clinical outcomes 39 . In 17 the latter instance, we suspect that antibiotics do not solely target the pathogen, but rather disrupt 18 the complex metabolic interactions that supply them with substrates for growth and stimulate 19 their pathogenicity. 20
This work raises the question of the importance of mucin-degrading anaerobes in late 21 stages of CF disease when bacterial diversity often declines and becomes predominated by P. 22 aeruginosa 40 . In severe disease states, it is known that chronic airway infections can lead to a 23 'leaky' lung epithelium that allows bioavailable metabolites to reach the epithelial surface 41 . 1
Additionally, persistent P. aeruginosa infections incite a neutrophil-dominant inflammatory 2 response that is associated with increased concentrations of host-derived proteases 42 . Human 3 neutrophil elastase, for example, is capable of cleaving glycoproteins into free amino acids, and 4 has been implicated in the progression of lung disease 43 . Moreover, neutrophilic burst may also 5 contribute to the bioavailable nutrient pool, potentially diminishing the need for anaerobic 6 fermenters as P. aeruginosa populations colonize the airway niche and incite a heightened 7 immune response. We are currently investigating the temporal dynamics of both host and 8 microbiota mucin degradation across the spectrum of disease severity. 9
Altogether, this study underscores the importance of defining the underlying microbial 10 ecological dynamics associated with airway disease. In particular, our data warrant further 11 studies of targeted therapies towards fermentative organisms and their metabolisms that may 12 contribute to the establishment and progression of chronic CF lung infections. In a broader 13 context, the presence of both oral anaerobes and known pathogens in other, mucus rich 14 environmentschronic obstructive pulmonary disease, chronic sinusitis, ventilator-associated 15 pneumoniassuggests that mucin fermentation and metabolic cross-feeding may be a 16 widespread disease phenomenon. A more detailed understanding of these metabolic interactions 17 are vital to the development of effective therapeutic strategies and improved clinical outcomes. 18
Methods

20
Bacterial strains and culture conditions. P. aeruginosa PA14 and Staphylococcus aureus MN8 21 were obtained from D.K. Newman (California Institute of Technology). Clinical strains of P. aeruginosa (CI46, CI47) and A. xylosoxidans MN001 44 were isolated from patients enrolled in 23 this study. Strains were routinely cultured in Luria Bertani medium or a minimal mucin medium containing 60mM KH 2 PO 4 (pH 7.4), 90mM NaCl, 1mM MgSO 4 , 10 g L -1 (or 15 g L -1 where 1 specified) porcine gastric mucin (Sigma), and a trace minerals mix 45 . During preparation, mucin 2 was autoclaved, dialyzed using a 13 kDa molecular weight cutoff membrane, clarified by 3 centrifugation, followed by passage through a 0.45 μm Millipore filter to sterilize soluble intact 4 glycoproteins. Glucose and NH 4 Cl were supplemented at 13mM and 60mM, respectively, where 5 specified. MEM essential and non-essential amino acid mixes (Sigma) were added at a final 6 concentration of 0.5X the recommended concentration. For enrichment growth, ~100 μL of 7 sputum was used to inoculate minimal mucin medium under anoxia (95% N 2 , 5% CO 2 ) and the 8 remainder was frozen at -80°C. Following 48h of incubation at 37°C, 100 μL of culture was used 9 to inoculate a second anaerobic culture tube and allowed to grow for 48h. Genomic DNA was 10 isolated from both the initial sputum sample and enrichment cultures, and bacterial community 11 composition was determined using 16S rRNA gene sequencing. Supplementary Table 2 . Amplicons were quantified using PicoGreen (Life Technologies, 18 Carlsbad, CA), normalized, pooled, and ~1 g of material was concentrated to 10μl using 1.8x 19
AMPureXP beads (Beckman Coulter, Brea, CA). The pooled sample was size selected at 427bp 20 +/-20% on a Caliper XT DNA 750 chip (Caliper Life Science, Hopkinton, MA). Amplicons 21 were cleaned using AMPureXP beads and analyzed using an Agilent Bioanalyzer Chip (Agilent 22
Technologies, Santa Clara, CA). The final pooled sample was then diluted to 2 nM, 10μl was 23 denatured using 0.2N NaOH, diluted to 8pM in HT1 buffer, spiked with 15% phiX, heat 1 denatured for 2 min, and sequenced using a MiSeq 600 cycle v3 kit (Illumina, San Diego, CA). 2 A defined mock community and reagent blanks were also sequenced as controls. 3
Raw sequence reads were obtained from UMGC and analyzed using a QIIME 47 pipeline 4 developed by the UMGC. Briefly, read pairs were stitched together and 16S amplicon primers 5 were removed using PandaSeq (version 2.7) 48 . Fastq files were merged and sequence IDs 6 converted to QIIME format using a custom perl script. Chimeric sequences were detected using 7 the QIIME (version 1.8.0) script identify_chimeric_seq.py function, using the usearch61 method. 8
Open reference OUT picking was performed using the pick_open_reference_otus.py script, using 9 the usearch61 method and the Greengenes 13_8 16S rRNA reference database 49 clustered at 97% 10 similarity. MetaStats was used to detect differentially abundant features of the mucin-enriched 11 bacterial community 50 . All fastq files are available online at the NIH Sequence Read Archive 12 (http://www.ncbi.nlm.nih.gov/bioproject) under BioProject accession number SRP067035. 13
In vitro cross-feeding. A saliva-derived mucin-fermenting bacterial community (Supplementary 14 Figure 1 ) was used to inoculate 2 mL of mucin (15g/L) minimal medium in molten 1% agar at 15 50ºC in a glass culture tube under anoxic conditions ( Fig. 2A) . Upon solidification, an additional 16 2 mL of molten minimal medium agar (without mucin) was inoculated with a 1/10000 dilution of 17 an overnight culture of P. aeruginosa (or other strains where specified). Samples were then 18 poured over the mucin fermenting community. Tubes without mucin-fermenters were used as 19 controls. After solidification, co-cultures were placed at 37ºC for 65 hours. Agar plugs were then 20 removed from the upper phase, sectioned and normalized by weight, followed by 21 propionate [ 13 C 1 ]) and acidified using 2 μl of 12N HCl. After equilibration at 60°C for 2h, 21 carboxen/ polydimethylsiloxane solid phase microextraction (SPME) fiber was used to adsorb 22 the headspace at 60°C for 30min. Acids were then desorbed into the gas chromatograph inlet for 23 2 min. A 30 m x 0.32 mm ID DB-624 column attached to a Thermo Electron Trace gas 1 chromatograph with helium carrier gas (2.0 ml/min) was used for separation of analytes. A 2 Waters Micromass Quatro GC mass spectrometer was used for detection and quantification of 3 target ions. Significance between sputum and saliva samples were determined by paired 4
Student's t-test. 5 RNA isolation, purification, and qRTPCR.
6
To quantify P. aeruginosa gene expression in vivo, sputum (n=17) was expectorated into 7
RNAlater and immediately frozen to preserve the gene expression profile. Frozen sputum was 8 thawed in TriZol (Life Technologies), homogenized using ceramic beads and purified according 9 to the manufacturer's protocol. RNA was concentrated using the Clean & Concentrator kit 10 (Zymo) and de-salted using Turbo DNA-free (Life Technologies). Bacterial RNA was enriched 11 using the MicrobEnrich kit (Life Technologies), and purity was confirmed using Qubit 12 (LifeTechnologies) spectrophotometry. qRTPCR was performed as previously described 51 
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The authors declare no competing financial interests. patients. Acetate concentrations were significantly higher in sputum (p = 0.006, **). 8 Figure 6 . In vitro expression (left) of acsA ( ) and prpD ( ) are upregulated in response to 9 acetate and propionate, respectively. prpD is preferentially expressed in the presence of both 10 acetate and propionate. Data shown are biological triplicate measurements for PA14. In vivo 11 (right), prpD is upregulated (5.4 fold ± 3.1) while acsA is not (1.0 fold ± 1.3 SD) (n=17). p ≤ 12 0.01, **; p ≤ 0.001, ***; p ≤ 0.0001, ****. 13
